Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Butylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylamine SCHEMBL10449621 | 1.00 | — | — | |
| Butylamine SCHEMBL2051232 | 1.00 | — | — | |
| Butylamine SCHEMBL332657 | 0.96 | — | — | |
| Butylamine SCHEMBL34462087 | 0.96 | DNM1 (0.67) | — | |
| Butylamine SCHEMBL6473376 | 0.96 | DNM1 (0.67) | — | |
| Butylamine SCHEMBL6933505 | 0.96 | — | — | |
| Butylamine SCHEMBL2800745 | 0.96 | DNM1 (0.67) | — | |
| Butylamine SCHEMBL6234410 | 0.96 | — | — | |
| Butylamine SCHEMBL5001577 | 0.96 | DNM1 (0.67) | — | |
| Butylamine SCHEMBL27308164 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107540587-B | The purification process of paricalcitol | 江苏神龙药业股份有限公司 | 2019-11-22 | — | — | CN | claimed |
| CN-107428770-B | Methods and systems for camptothecin analog synthesis | 维瓦西塔斯肿瘤学公司 | 2019-10-01 | — | — | CN | claimed |
| CN-107540588-B | The preparation method of paricalcitol | 江苏神龙药业股份有限公司 | 2019-08-27 | — | — | CN | claimed |
| CN-105294426-B | Azetidinone compounds Preparation Method And Their Intermediate | 浙江海正药业股份有限公司 | 2019-05-14 | — | — | CN | claimed |
| CN-104803858-B | Method for preparing tetrabutylammonium fluoride trihydrate | 东莞东阳光科研发有限公司 | 2019-03-01 | — | — | CN | claimed |
| CN-108794561-A | A kind of Abiraterone acetate highly finished product synthetic method | 徐州工业职业技术学院 | 2018-11-13 | — | — | CN | claimed |
| CN-108546279-A | A kind of Abiraterone acetate highly finished product are raw materials used and its synthetic method | 徐州工业职业技术学院 | 2018-09-18 | — | — | CN | claimed |
| CN-108440687-A | The preparation method of alkyl xylan | 北京林业大学 | 2018-08-24 | — | — | CN | claimed |
| CN-106008302-B | A kind of vitamin D2The preparation method of derivative | 无锡贝塔医药科技有限公司 | 2018-08-07 | — | — | CN | claimed |
| CN-107540587-A | The purification process of paricalcitol | 江苏神龙药业有限公司 | 2018-01-05 | — | — | CN | claimed |
| CN-105294426-A | Preparation method for azacyclobutanone compound and intermediate of azacyclobutanone compound | ZHEJIANG HISUN PHARM CO LTD | 2016-02-03 | — | — | CN | claimed |
| CN-104803858-A | Method for preparing tetrabutylammonium fluoride trihydrate | DONGGUAN CHANG AN DONGYANGGUANG ALUMINUM R & D CO | 2015-07-29 | — | — | CN | claimed |
| CN-104513187-A | Ezetimibe synthesis method and Ezetimibe intermediate synthesis method | ARROMAX PHARMACEUTICAL TECHNOLOGY SUZHOU CO LTD | 2015-04-15 | — | — | CN | claimed |
| CN-103923217-A | 6-amino caproic acid cellulose ester as well as synthetic method and application thereof | UNIV SHAANXI NORMAL | 2014-07-16 | — | — | CN | claimed |
| CN-103086937-A | Method for synthesizing paricalcitol | SHANGHAI PUYI CHEMICAL TECHNOLOGY CO LTD | 2013-05-08 | — | — | CN | claimed |
| CN-101817836-B | Method for preparing imidazo[2,1-b]thiazole derivative by catalysis of copper salt | UNIV ZHEJIANG | 2012-02-29 | — | — | CN | claimed |
| CN-102351622-A | Method for preparing (Z)-1,2-disulfide-1-olefin by catalysis of metal copper salt | UNIV ZHEJIANG | 2012-02-15 | — | — | CN | claimed |
| EP-2406227-A1 | PROCESS FOR MANUFACTURING 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY) HEXYL]AMINO}-1- HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE. | Almirall S.A. (ES) | 2012-01-18 | — | — | EP | claimed |
| WO-2010102831-A1 | PROCESS FOR MANUFACTURING 5-(2-{[6-(2,2-DIFLUORO-2-PHENYIETHOXY) HEXYL]AMINO}-L- HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE. | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | WO | claimed |
| CN-101817836-A | Method for preparing imidazo[2,1-b]thiazole derivative by catalysis of copper salt | UNIV ZHEJIANG | 2010-09-01 | — | — | CN | claimed |